{
    "ticker": "NVAC",
    "name": "NovaVax, Inc.",
    "description": "NovaVax, Inc. is a biotechnology company focused on the development, commercialization, and manufacturing of innovative vaccines for the prevention of serious infectious diseases. Founded in 1987, NovaVax aims to leverage its proprietary technology platforms to address unmet medical needs in the global vaccine market. The company is primarily known for its vaccine candidates targeting diseases such as COVID-19, influenza, and other viral infections. NovaVax's lead product candidate, NVX-CoV2373, is a protein-based vaccine that has shown promising efficacy and safety data in clinical trials, positioning it as a potential key player in the fight against the COVID-19 pandemic. The company's innovative approach includes the use of its Matrix-M adjuvant, which enhances immune responses and is designed to improve vaccine performance. In addition to COVID-19, NovaVax is also working on vaccines for seasonal and pandemic influenza, aiming to deliver effective solutions to global health challenges. The company's mission is to provide high-quality vaccines that are accessible to populations around the world, thereby contributing to public health and disease prevention.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Gaithersburg, Maryland, USA",
    "founded": "1987",
    "website": "https://www.novavax.com",
    "ceo": "Stanley Erck",
    "social_media": {
        "twitter": "https://twitter.com/Novavax",
        "linkedin": "https://www.linkedin.com/company/novavax/"
    },
    "investor_relations": "https://investors.novavax.com",
    "key_executives": [
        {
            "name": "Stanley Erck",
            "position": "CEO"
        },
        {
            "name": "John Trizzino",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Vaccines",
            "products": [
                "NVX-CoV2373 (COVID-19 Vaccine)",
                "NanoFlu (Influenza Vaccine)"
            ]
        }
    ],
    "seo": {
        "meta_title": "Novavax, Inc. | Innovative Vaccine Development",
        "meta_description": "Explore Novavax, Inc., a leader in vaccine innovation focused on developing high-quality vaccines for infectious diseases. Learn about our mission and products.",
        "keywords": [
            "Novavax",
            "Vaccines",
            "COVID-19",
            "Influenza",
            "Biotechnology",
            "Infectious Diseases"
        ]
    },
    "faq": [
        {
            "question": "What does Novavax specialize in?",
            "answer": "Novavax specializes in the development of innovative vaccines for infectious diseases."
        },
        {
            "question": "Who is the CEO of Novavax?",
            "answer": "Stanley Erck is the CEO of Novavax, Inc."
        },
        {
            "question": "Where is Novavax headquartered?",
            "answer": "Novavax is headquartered in Gaithersburg, Maryland, USA."
        },
        {
            "question": "What are Novavax's main products?",
            "answer": "Novavax's main products include NVX-CoV2373 for COVID-19 and NanoFlu for influenza."
        },
        {
            "question": "When was Novavax founded?",
            "answer": "Novavax was founded in 1987."
        }
    ],
    "competitors": [
        "MRNA",
        "PFE",
        "JNJ",
        "AZN"
    ],
    "related_stocks": [
        "AAPL",
        "GOOGL",
        "AMZN",
        "MSFT"
    ]
}